Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

Area of Science:

• Hematology
• Oncology
• Clinical Research

Background:

• Multiple myeloma (MM) is an incurable hematologic malignancy with frequent relapses.
• Pomalidomide and low-dose dexamethasone (Pom-Dex) is an effective treatment for relapsed/refractory multiple myeloma (RRMM).
• Outcomes for patients with RRMM after pomalidomide therapy remain poor, though some experience prolonged survival.

Purpose of the Study:

• To analyze treatment patterns, response rates, and survival outcomes in RRMM patients following Pom-Dex therapy.
• To identify prognostic factors associated with improved survival after Pom-Dex treatment in RRMM.

Main Methods:

• Retrospective analysis of 134 RRMM patients from two IFM studies treated with Pom-Dex until progression.
• Evaluation of subsequent therapies, response rates (overall response rate, stable disease), and overall survival (OS).
• Statistical analysis to identify factors correlating with better outcomes.

Main Results:

• 70% of patients received further therapy after Pom-Dex.
• One-third of treated patients achieved a response, and one-third maintained stable disease.
• Median OS was 12 months; 22% and 12.5% survived beyond 2 and 3 years, respectively.

Conclusions:

• Patients with RRMM progressing after Pom-Dex can benefit from subsequent treatment lines.
• A subset of patients demonstrates prolonged overall survival after further therapy.
• An active treatment approach, guided by prognostic factors, is recommended for RRMM patients post-Pom-Dex.